Počet záznamov: 1
PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer
- PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer / Y. Zhang ... [et al.]. Neoplasma Vol. 61, no. 4 (2014), s. 461-467
článok
Počet záznamov: 1